This is a multi-part message in MIME format.
--part0_896283878_boundary
Content-ID: <[log in to unmask]>
Content-type: text/plain; charset=US-ASCII
NEOTROFIN Reported to Stimulate Nerve Regeneration
IRVINE, Calif.--(BUSINESS WIRE)-- May 21, 1998--NeoTherapeutics, Inc.
(Nasdaq: NEOT; NEOTW) announced today that researchers from North Carolina
and Canada reported that the Company's lead product candidate, AIT-082
(NEOTROFIN(tm)), has been shown to stimulate nerve regeneration in tissue
culture and in animals.
At the 6th International Symposium on Adenosine and Adenine Nucleotides,
held in Ferrara, Italy, Dr. Bernhard H.J. Juurlink of the Department of
Anatomy and Cell Biology at the University of Saskatchewan, Saskatoon,
Saskatchewan, Canada, reported that treatment of hippocampal neurons with
AIT-082 caused nerve outgrowth and enhanced branching of the nerve processes.
Hippocampal neurons have been reported to be involved in memory function.
"Glutamate excitotoxicity is implicated in a number of neurodegenerative
diseases," Dr. Juurlink stated. "AIT-082 is potentially therapeutic in a
number of neurodegenerative disorders. We have demonstrated in hippocampal
neurons grown in culture that AIT-082 not only promotes neurite formation in
developing hippocampal neurons, but it prevents much of the neurite
degeneration following exposure to excessive amounts of the neurotransmitter
glutamate."
Dr. Julio J. Ramirez, the R. Stuart Dickson Professor of Psychology,
Davidson College, Davidson, North Carolina, demonstrated in animals that
after destruction of a discreet area of the brain involved in memory,
treatment with AIT-082 caused re-growth of neurons into the damaged area.
These effects were seen after only four days of treatment with AIT-082.
"Since the reorganization of brain circuitry has been shown to contribute
to recovery of memory function after injury or degeneration in areas crucial
to learning and memory," Dr. Ramirez stated, "the possibility that AIT-082
might enhance this reorganization opens up marvelous opportunities to promote
recovery of function in injured and diseased brains."
NeoTherapeutics is engaged in the discovery and development of drugs that
act on the central nervous system to repair nerve cells and treat
neurodegenerative diseases such as Alzheimer's disease, spinal cord injury,
Parkinson's disease and stroke, as well as other neurological conditions such
as migraine. NeoTherapeutics' products are orally administered and based
upon patented technologies. AIT-082 (NEOTROFIN(tm)) is currently in human
clinical trials for the treatment of Alzheimer's disease. For additional
company information, visit the NeoTherapeutics website at
www.neotherapeutics.com.
This press release contains forward-looking statements regarding future
events and the future performance of NeoTherapeutics that involve risks and
uncertainties that could cause actual results to differ materially. These
risks include, but are not limited to, the biological activity, side effect
profile and efficacy of AIT-082, the early stage of product development, the
potential need for additional funding, the initiation and completion of
clinical trials and dependence on third parties for clinical testing,
manufacturing and marketing. These risks are described in further detail in
the Company's annual and quarterly reports filed with the Securities and
Exchange Commission.
--part0_896283878_boundary
Content-ID: <[log in to unmask]>
Content-type: message/rfc822
Content-transfer-encoding: 7bit
Content-disposition: inline
From: Gregfmason <[log in to unmask]>
Return-path: <[log in to unmask]>
To: [log in to unmask]
Subject: PD Stuff
Date: Wed, 27 May 1998 02:22:59 EDT
Organization: AOL (http://www.aol.com)
Mime-Version: 1.0
Content-type: text/plain; charset=US-ASCII
Content-transfer-encoding: 7bit
Subj: NEOTROFIN Reported to Stimulate Nerve Regeneration
Date: 98-05-21 10:09:30 EDT
From: AOL News
BCC: Gregfmason
NEOTROFIN Reported to Stimulate Nerve Regeneration
IRVINE, Calif.--(BUSINESS WIRE)-- May 21, 1998--NeoTherapeutics, Inc.
(Nasdaq: NEOT; NEOTW) announced today that researchers from North Carolina
and Canada reported that the Company's lead product candidate, AIT-082
(NEOTROFIN(tm)), has been shown to stimulate nerve regeneration in tissue
culture and in animals.
At the 6th International Symposium on Adenosine and Adenine Nucleotides,
held in Ferrara, Italy, Dr. Bernhard H.J. Juurlink of the Department of
Anatomy and Cell Biology at the University of Saskatchewan, Saskatoon,
Saskatchewan, Canada, reported that treatment of hippocampal neurons with
AIT-082 caused nerve outgrowth and enhanced branching of the nerve processes.
Hippocampal neurons have been reported to be involved in memory function.
"Glutamate excitotoxicity is implicated in a number of neurodegenerative
diseases," Dr. Juurlink stated. "AIT-082 is potentially therapeutic in a
number of neurodegenerative disorders. We have demonstrated in hippocampal
neurons grown in culture that AIT-082 not only promotes neurite formation in
developing hippocampal neurons, but it prevents much of the neurite
degeneration following exposure to excessive amounts of the neurotransmitter
glutamate."
Dr. Julio J. Ramirez, the R. Stuart Dickson Professor of Psychology,
Davidson College, Davidson, North Carolina, demonstrated in animals that
after destruction of a discreet area of the brain involved in memory,
treatment with AIT-082 caused re-growth of neurons into the damaged area.
These effects were seen after only four days of treatment with AIT-082.
"Since the reorganization of brain circuitry has been shown to contribute
to recovery of memory function after injury or degeneration in areas crucial
to learning and memory," Dr. Ramirez stated, "the possibility that AIT-082
might enhance this reorganization opens up marvelous opportunities to promote
recovery of function in injured and diseased brains."
NeoTherapeutics is engaged in the discovery and development of drugs that
act on the central nervous system to repair nerve cells and treat
neurodegenerative diseases such as Alzheimer's disease, spinal cord injury,
Parkinson's disease and stroke, as well as other neurological conditions such
as migraine. NeoTherapeutics' products are orally administered and based
upon patented technologies. AIT-082 (NEOTROFIN(tm)) is currently in human
clinical trials for the treatment of Alzheimer's disease. For additional
company information, visit the NeoTherapeutics website at
www.neotherapeutics.com.
This press release contains forward-looking statements regarding future
events and the future performance of NeoTherapeutics that involve risks and
uncertainties that could cause actual results to differ materially. These
risks include, but are not limited to, the biological activity, side effect
profile and efficacy of AIT-082, the early stage of product development, the
potential need for additional funding, the initiation and completion of
clinical trials and dependence on third parties for clinical testing,
manufacturing and marketing. These risks are described in further detail in
the Company's annual and quarterly reports filed with the Securities and
Exchange Commission.
--part0_896283878_boundary--
